Reports Q2 revenue $37.9M, consensus $35.92M. The Company reported cash and short-term investments of $190.7 million as of June 30, 2025, excluding restricted cash. The Company believes that it has sufficient resources to fund operations for at least twelve months from the issuance of the Company’s Quarterly Report on Form 10-Q.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRMD:
- CRMD Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- CorMedix Inc. Advances Pediatric Dialysis Safety with New Clinical Study
- CorMedix’s DEFENCATH® Study: A Potential Game-Changer in Infection Prevention
- CorMedix Completes $82.2 Million Stock Offering
- Circle initiated, Disney upgraded: Wall Street’s top analyst calls